Elanco Animal Health (ELAN)
(Delayed Data from NYSE)
$14.07 USD
-0.43 (-2.97%)
Updated Nov 8, 2024 04:00 PM ET
After-Market: $14.05 -0.02 (-0.14%) 5:54 PM ET
3-Hold of 5 3
B Value D Growth F Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$14.07 USD
-0.43 (-2.97%)
Updated Nov 8, 2024 04:00 PM ET
After-Market: $14.05 -0.02 (-0.14%) 5:54 PM ET
3-Hold of 5 3
B Value D Growth F Momentum D VGM
Zacks News
Elanco Animal Health Incorporated (ELAN) Q3 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Elanco Animal Health Incorporated (ELAN) delivered earnings and revenue surprises of 15.38% and 1.80%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Healthcare Stock Earnings Slated on Nov 6: HUM, ELAN & More
by Zacks Equity Research
Rise in senior population, shift of care to lower-cost settings and decline in unemployment are likely to have driven healthcare sector earnings.
Earnings Preview: Elanco Animal Health Incorporated (ELAN) Q3 Earnings Expected to Decline
by Zacks Equity Research
Elanco Animal Health Incorporated (ELAN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zoetis Appoints Kristin Peck as New CEO, Alaix to Retire
by Zacks Equity Research
Zoetis (ZTS) names executive vice president Kristin Peck as the new CEO, effective Jan 1, 2020.
Zoetis (ZTS) Receives EC Approval for Simparica Trio in Dogs
by Zacks Equity Research
Zoetis' (ZTS) leading animal health portfolio gets a boost with the approval of Simparica Trio.
Bayer Inks $7.6B Deal to Divest Animal Health Unit to Elanco
by Zacks Equity Research
Bayer (BAYRY) inks deal with Elanco to divest its animal health business for $7.6 billion.
Bayer Sells Animal Health Division to Elanco: Now What?
by Mitchell Moore
On Tuesday, Bayer (BAYRY) announced the sale of its animal-health division to American competitor Elanco (ELAN), for a net price of $7.6 billion. The deal is expected to close in mid-2020 after regulatory approval.
Lilly (LLY) Down Despite Q1 Earnings Beat on Sales View Cut
by Zacks Equity Research
Eli Lilly's (LLY) earnings beat estimates in Q1. Stock falls in pre-market trading as the company lowers its full-year revenue forecast.
Do Options Traders Know Something About Elanco Health (ELAN) Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to Elanco Health (ELAN) stock based on the movements in the options market lately.
Lilly to Begin Exchange Offer for Sale of Balance Elanco Stake
by Zacks Equity Research
Eli Lilly (LLY) to initiate an exchange offer for shareholders to divest its remaining ownership interest in Elanco
Eli Lilly (LLY) Q4 Earnings Coming Up: What's in the Cards?
by Zacks Equity Research
Eli Lilly and Company's (LLY) new drugs like Trulicity, Taltz and Jardiance are performing well. Let's see if these along with its older products lead the company to an earnings beat.
The Zacks Analyst Blog Highlights: Intuitive Surgical, Illumina, HCA, Elanco Animal and Humana
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Intuitive Surgical, Illumina, HCA, Elanco Animal and Humana
5 Great Medical Stocks to Buy Ahead of Q4 Earnings
by Swarup Gupta
A Reuters review of Wall Street Research firms reveals that health care is the most favored of the S&P 500's 11 major sectors.
Lilly's Shares Rise on Robust 2019 View, Dividend Hike
by Zacks Equity Research
Eli Lilly's (LLY) shares rise 3% on an upbeat outlook for 2019. It also hikes quarterly dividend by 15%.
Lilly (LLY) Tops Q3 Earnings, Lifts 2018 Outlook, Stock Up
by Zacks Equity Research
Eli Lilly (LLY) beats estimates for earnings but misses the same for sales. The company raises its previously issued outlook for adjusted earnings. Stock rises in pre-market trading.